Partnership to focus on empowering women to take control of their health and health options
PRINCETON, NJ, Sept. 28, 2021 (GLOBE NEWSWIRE) – Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s health company, today announced a partnership with U.S. women’s soccer legend Carli Lloyd. The partnership with Agile will focus on raising awareness of women’s health issues and Agile’s commitment to improving women’s health care.
Lloyd, who will play her final game for the US women’s national team against South Korea on October 26, has been drawn to the company’s mission to meet the health needs of women today.
“I am excited to be working with a company that is solely dedicated to women’s health,” said Lloyd. “My goal is to work with organizations that focus on things that are important to me. Staying healthy has been a priority in my career in the field and will continue to be as I move on to my next chapter. Agile’s focus on providing women with options and knowledge when it comes to their health decisions is a mission I am proud of. And the fact that I’m a Jersey girl representing a New Jersey company makes it even better. “
Agile built its brand around a commitment to addressing the health needs of women. In February 2020, the company received approval from the US Food and Drug Administration (FDA) for its first product, the Twirla® transdermal system (levonorgestrel and ethinylestradiol), a weekly contraceptive patch. There are currently four more contraceptives in the pipeline.
“Carli’s ‘always believe and never give up’ attitude fits in with what Agile Therapeutics believes as a company,” said Al Altomari, CEO of Agile Therapeutics. “We have worked selectively with the right partners at the right time, and Carli is someone who fits seamlessly into our corporate culture, aligns with our values, and understands the importance of empowering women, especially young women, to push their boundaries . “Believe in yourself and not compromise, especially when it comes to your health care.”
The story goes on
As a growing company, Agile sees this partnership as an opportunity to further develop its culture and corporate brand by working with executives who share the company’s values and mission.
“Our short-term goal is to bring Twirla to the contraceptive market and our long-term mission remains the same: to build a robust women’s health franchise, and Carli is a crucial piece of that puzzle,” said Altomari. “She has been a vocal advocate for women and her voice is an important voice in the national debate on women’s health and women’s health needs. We want to make sure that we communicate our message and our commitment to women’s health authentically and comprehensibly. We share this mission with Carli and we are proud to welcome her to our team. “
About Agile Therapeutics, Inc.
Agile Therapeutics is a women’s health company dedicated to meeting the unmet health needs of women today. Our products and product candidates are designed to provide women with contraceptive options that allow them to take a daily pill without committing to a longer-acting method. Our first product, Twirla® (levonorgestrel and ethinylestradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology called Skinfusion®, which enables drug delivery through the skin. For more information, see the company website at www.agiletherapeutics.com. The Company may from time to time post material, nonpublic information on the Company’s website.
About Twirla®
Twirla (levonorgestrel and ethinylestradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active substances levonorgestrel (LNG), a type of gestagen, and ethinylestradiol (EE), a type of estrogen. Twirla is indicated as a method of contraception in women of childbearing potential with a body mass index (BMI) <30 kg / m2 for whom a combined hormonal contraceptive is suitable. Health care providers (HCPs) are advised to consider the reduced effectiveness of Twirla in women with a BMI ≥ 25 to <30 kg / m2 prior to prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg / m2. Twirla is contraindicated in women over 35 years of age who smoke. Smoking cigarettes increases the risk of serious cardiovascular events from CHD consumption. Twirla should be used once a week for three weeks, followed by one week without the patch.
Media inquiries:
Matt Riley
Head of Investor Relations and Corporate Communications
mriley@agiletherapeutics.com
source https://www.bisayanews.com/2021/09/28/agile-therapeutics-partners-with-carli-lloyd-u-s-womens-soccer-star-and-four-time-olympian-to-bring-awareness-to-womens-health-topics/
No comments:
Post a Comment